Fairmount Funds Management LLC bought $18.2M of Crescent Biopharma (CBIO)
Executed Dec 4 2025, disclosed Dec 8 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 8 2025), the stock returned -16.4% (delay-adjusted); from the execution session (Dec 4 2025), -28.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Fairmount Funds Management LLC (Director) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (6 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 6 priced purchase filings, the average 21-session return was +5.9% from execution and +8.5% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.
Healthcare · Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→853,450 sh × $14.50
Exec Jul 16
Filed Jul 20 · 5:30 PM ET